STADA: Nine-Month Records Confirm Optimistic Outlook
11/18/2003 . Ad hoc Release
STADA achieved new records in sales and earnings in the first nine months of 2003. Consolidated sales rose by +17% to EUR 545.7 million compared to the prior year period. Sales in the core segments (generics, branded products and special pharmaceuticals), which account for 95% of total sales, increased by a total of +25%. Consolidated net income rose to EUR 34.8 million (up +21% compared to 1-9/2002), earnings before taxes (EBT) to EUR 60.3 million (up +26%), earnings before interest and taxes (EBIT) to EUR 71.3 million (up +25%) and EBITDA to EUR 97.1 million (up +25%). Earnings per share reached EUR 1.74 in the first nine months of 2003, (EUR 1.51 in 1-9/2002 with a roughly -5% lower average number of shares than in the prior year) and diluted earnings per share (EPS diluted pursuant to IAS 33.24) were EUR 1.65 (EUR 1.51).
On this basis, STADA is confident that it will be able to achieve its goal of sales and earnings growth in the double-digit percentage range for all of 2003 and thus the eighth record year in a row. From the present perspective, the Executive Board of STADA also still anticipates being able to increase sales and earnings in the double-digit percentage range in the coming 2004 fiscal year - irrespective of expected health policy challenges in individual national markets.
You'll find the complete report on the first nine months and the press release on the Internet at www.stada.com.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506